1. Home
  2. ATLX vs MDXH Comparison

ATLX vs MDXH Comparison

Compare ATLX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlas Lithium Corporation

ATLX

Atlas Lithium Corporation

HOLD

Current Price

$4.37

Market Cap

149.7M

Sector

Industrials

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.87

Market Cap

149.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATLX
MDXH
Founded
2011
2003
Country
Brazil
Belgium
Employees
N/A
N/A
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
149.7M
149.0M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
ATLX
MDXH
Price
$4.37
$0.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$12.00
$7.67
AVG Volume (30 Days)
990.5K
791.4K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
47.08
N/A
EPS
N/A
N/A
Revenue
$92,491.00
N/A
Revenue This Year
$64,564.67
$30.78
Revenue Next Year
$785.59
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.60
$0.68
52 Week High
$8.25
$5.33

Technical Indicators

Market Signals
Indicator
ATLX
MDXH
Relative Strength Index (RSI) 41.03 14.49
Support Level $4.26 N/A
Resistance Level $5.21 $2.30
Average True Range (ATR) 0.51 0.13
MACD -0.17 -0.11
Stochastic Oscillator 12.16 11.29

Price Performance

Historical Comparison
ATLX
MDXH

About ATLX Atlas Lithium Corporation

Atlas Lithium Corp is a mineral exploration and development company with lithium projects and exploration properties in other critical and battery minerals, including nickel, rare earth, graphite, and titanium, to power the increased demand for electrification. Its focus is on developing its hard-rock lithium project Minas Gerais Lithium Project, located in Minas Gerais State in Brazil. The company is focused on producing and selling lithium concentrate, a key ingredient for the battery supply chain.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: